Eli Lilly’s Ruboxistaurin Poised to Transform the Diabetic Neuropathy Drug Marke

Ruboxistaurin can possibly shift the market from pain control to disease modification, according to a new report from Decision Resources. According to the new Pharmacor study entitled Diabetic Neuropathy, Eli Lilly’s ruboxistaurin promises to be the first drug with disease-modifying potential that will launch beyond Japan. (Epalrestat, available in Japan since 1995, is thought by physicians to be only moderately effective.)

“Although ruboxistaurin has performed poorly in trials for diabetic retinopathy, interviewed experts remain hopeful that, if this agent is administered early enough in the disease process, it will reduce disease progression of distal symmetrical polyneuropathy, the most common clinical manifestation of neuropathy among diabetics,” said Carilee Berg, Ph.D., analyst at Decision Resources.
Decision Resources, Inc, Report